IL6 and COVID-19: These include patients’ age, and coexistence of chronic disease such as cardiovascular disease, diabetes, and hypertension.23 Indeed, COVID-19 patents with chronic disease such as diabetes have been shown to have increased pro-inflammatory mediators IL-6, suggesting these patients are at higher risk of developing more serious complications of COVID-19.24,25 In addition, males have been shown to have been more at risk of developing thrombotic complications.